Identification of IL20RB as a Novel Prognostic and Therapeutic Biomarker in Clear Cell Renal Cell Carcinoma

Abstract

Background. Clear cell renal cell carcinoma (ccRCC) is a type of life-threatening malignant tumor of the urinary system. IL20RB, interleukin 20 receptor subunit beta, is a cytokine receptor subunit coding gene and was initially found to play a vital role in human cancers, while its role in ccRCC still remains unclear. Methods. In this work, we explored the prognostic value and therapeutic potential of IL20RB in ccRCC mainly by online tools. Firstly, we used UALCAN and GEPIA to explore the expression profile and prognostic value of IL20RB in various cancers; the expression profile in tumor cell lines was also analysed with CCLE and Expression Atlas. Then, we decided to focus on ccRCC for further analysis; we further demonstrated the significant correlation between expression and clinical features by GEPIA and UALCAN. In order to reveal the potential intrinsic mechanism responsible for the upregulation of IL20RB in ccRCC, we made genetic alternation analysis and methylation analysis. cBioPortal was used for genetic alternation analysis. UALCAN, MethSurv, and Xena were used for methylation analysis. To learn details of how IL20RB might function in ccRCC, we further conducted functional analysis and immune infiltration analysis. STRING and GSEA were used to do functional analysis. TIMER was used for immune infiltration analysis; KM plotter was used for survival analysis. Results. Results show that IL20RB is upregulated in ccRCC, and low methylation may be responsible for its upregulation. Both high expression and low methylation of IL20RB predict worse survival, and both have a strong positive correlation with clinical characteristics. In addition, results indicate that there exists a crosstalk between IL20RB and neutrophils. Furthermore, the immune microenvironment could influence the prognosis predicting ability of IL20RB. Conclusions. In conclusion, IL20RB plays an important role in ccRCC and is identified as a novel prognostic and potential therapeutic biomarker in ccRCC.

Construction and validation of risk model of EMT‐related prognostic genes for kidney renal clear cell carcinoma

“…A previous study found that IL20RB (interleukin 20 receptor subunit beta) functioned in papillary renal cell carcinoma through the EMT pathway 27 . A recent study reported that upregulated IL20RB is confirmed as a novel prognostic and therapeutic biomarker in KIRC, which is consistent with our results 28 . It was also reported that downregulated DDC is significantly associated with poor survival and an immune‐suppressive TME in KIRC 29 .…”

“…27 A recent study reported that upregulated IL20RB is confirmed as a novel prognostic and therapeutic biomarker in KIRC, which is consistent with our results. 28 It was also reported that downregulated DDC is significantly associated with poor survival and an immune-suppressive TME in KIRC. 29 Another study confirmed that decreased TEK expression had a poor prognosis for patients with KIRC.…”

Construction and verification of a novel prognostic risk model for kidney renal clear cell carcinoma based on immunity-related genes

“…Many human malignancies exhibit dysregulated IL20RB expression, which is remarkably high in KIRC. Previous work has shown that IL20RB can be used as a prognostic biomarker for tracking KIRC treatment (Guo et al, 2022). Abnormal expression of IFI30 has also been found in many human tumors.…”

IL22RA1/JAK/STAT Signaling Acts As a Cancer Target Through Pan-Cancer Analysis

“…Overexpression of IL10R2 contributes to colorectal carcinogenesis by IL22/STAT3 signaling (24). IL20RB has been proposed as a prognostic and therapeutic biomarker in clear cell renal cell carcinoma (25).…”